LIfT BioSciences Partners with Bayer Co.Lab for Enhanced Innovation
LIfT BioSciences, a pioneering company in the field of biotechnology, has made significant strides by entering into a partnership with Bayer HealthCare LLC. This alliance grants LIfT access to the highly regarded Co.Lab facilities located in Cambridge, Massachusetts, which is recognized as one of the foremost locations for biotechnological development and innovation.
Enhancing Research Capabilities
This collaboration opens up a wealth of opportunities for LIfT, providing access to advanced infrastructure and a highly supportive environment aimed at accelerating the company's innovative Immuno-Modulatory Alpha Neutrophil (IMAN) platform. This groundbreaking platform is specifically designed to tackle treatment resistance in solid tumors, a challenge that has critically limited the effectiveness of current therapies.
Leadership Insights on the Partnership
The Chief Executive Officer of LIfT BioSciences, Alex Blyth, expressed enthusiasm about the partnership, stating, "We are excited about aligning with The Bayer Group. They have a proven track record in utilizing cell therapies effectively across various areas. With access to Bayer’s world-class facilities and expertise, we are poised to drive our development efforts further forward. The Bayer Co.Lab presents an exceptional environment to foster our biotech innovations and bolster our presence as we transition into a clinical-stage company."
Contributions from Bayer Co.Lab
Fiona Mack, who heads Co.Lab Cambridge at Bayer HealthCare LLC, highlighted the Co.Lab's mission to bolster biotech companies by offering necessary resources and a collaborative network. “The Co.Lab was crafted to empower innovative biotech organizations with the necessary infrastructure to enhance their research and development processes. Our selection process for portfolio companies is rigorous, focusing on those with strong scientific merit and the potential to significantly impact healthcare. LIfT embodies this ideal with its forward-thinking approach in immunotherapy, making them an excellent addition to our environment,” she noted.
Gaining Additional Resources
About LIfT BioSciences
LIfT BioSciences is a biotech firm operating in the UK and Ireland, committed to developing a pioneering allogeneic alpha neutrophil immunotherapy. This revolutionary therapy aims to address treatment resistance in solid tumors by restoring immune functionality. The Immunomodulatory Alpha Neutrophils (IMANs) developed by LIfT function in a non-antigen-specific manner, effectively transforming the tumor microenvironment to elicit a robust immune response and lasting immunity.
The company is actively exploring collaborations with pharmaceutical license partners to create a comprehensive portfolio of engineered IMAN immunotherapies aimed at tackling various solid tumors. With their patented and innovative N-LIfT platform, produced using cutting-edge stem cells and genetic engineering techniques, LIfT is setting a new standard in immunotherapy.
Contact Information
For investors:
Alex Blyth
Email: ablyth@LIfTBioSciences.com
For media inquiries:
ICR Healthcare
Lindsey Neville, Namrata Taak, Evi Useh
Email: liftbiosciences@icrhealthcare.com
Frequently Asked Questions
1. What is the purpose of LIfT BioSciences' partnership with Bayer?
The partnership provides LIfT BioSciences with access to state-of-the-art lab facilities and resources to enhance their immunotherapy development.
2. What is the IMAN platform developed by LIfT BioSciences?
The IMAN platform is designed to overcome treatment resistance in solid tumors by enhancing immune response through the use of alpha neutrophils.
3. Where are Bayer's Co.Lab facilities located?
The facilities are situated in Cambridge, Massachusetts, a globally recognized hub for biotech innovation.
4. What unique advantages does LIfT gain from the Co.Lab facilities?
LIfT benefits from advanced infrastructure, collaborative research environments, and operational support systems tailored for early-stage biotechs.
5. How does LIfT BioSciences plan to expand its portfolio of therapies?
The company is actively seeking partnerships with pharmaceutical entities to develop a variety of engineered IMAN immunotherapies targeting different solid tumors.
